var data={"title":"Aztreonam (systemic): Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Aztreonam (systemic): Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/783820?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=aztreonam-systemic-patient-drug-information\" class=\"drug drug_patient\">see &quot;Aztreonam (systemic): Patient drug information&quot;</a> and <a href=\"topic.htm?path=aztreonam-systemic-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Aztreonam (systemic): Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F29768890\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Azactam;</li>\n      <li>Azactam in Dextrose</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F29768895\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antibiotic, Monobactam</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F29768948\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Urinary tract infection:</b> IM, IV: 500 mg to 1 g every 8 to 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Moderately severe systemic infections: </b> 1 g IV or IM or 2 g IV every 8 to 12 hours. <b>Note:</b> IV route preferred for septicemia, intra-abdominal abscess, or peritonitis; higher doses (8 to 12 g daily) may be needed for patients with cystic fibrosis (Zobell 2013) or other infections (Solomkin 2010).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Osteomyelitis, native vertebral due to </b>\n      <b>\n        <i>P. aeruginosa </i></b> <b>(off-label use): </b>IV: 2 g every 8 hours for 6 weeks. <b>Note: </b>Double coverage may be considered (ie, aztreonam plus an aminoglycoside) (IDSA [Berbari 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Severe systemic or life-threatening infections (eg, </b> <b><i>Pseudomonas aeruginosa</i></b>): IV: 2 g every 6 to 8 hours; maximum: 8 g daily. <b>Note:</b> Higher doses (8 to 12 g daily) may be needed for patients with cystic fibrosis (Zobell 2013) or other infections (Solomkin 2010).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Pneumonia, hospital-acquired or ventilator-associated (alternative therapy) (off-label dose): </b>IV: 2 g every 8 hours for 7 days; may consider shorter or longer durations depending on rate of clinical improvement. When used as empiric therapy, use in combination with an agent active against <i>Staphylococcus aureus</i> with or without an additional antipseudomonal agent (dependent on patient and institution-specific risk factors) (Kalil 2016).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Surgical (perioperative) prophylaxis (off-label use):</b> IV: 2 g within 60 minutes prior to surgery. Doses may be repeated in 4 hours if procedure is lengthy or if there is excessive blood loss (Bratzler 2013).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F29768947\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=aztreonam-systemic-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Aztreonam (systemic): Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Mild-to-moderate infections:</b> Infants &ge;9 months, Children, and Adolescents: IV: 30 mg/kg/dose every 8 hours; maximum: 120 mg/kg/day (8 g daily)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Moderate-to-severe infections:</b> Infants &ge;9 months, Children, and Adolescents: IV: 30 mg/kg/dose every 6 to 8 hours; maximum: 120 mg/kg/day (8 g daily)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Cystic fibrosis:</b> Infants &ge;9 months, Children, and Adolescents: IV: 50 mg/kg/dose every 6 to 8 hours (ie, up to 200 mg/kg/day); maximum: 8 g daily. <b>Note:</b> Higher doses (8 to 12 g daily) may be needed for patients with cystic fibrosis (Zobell 2013).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Surgical (perioperative) prophylaxis (off-label use):</b> Children &ge;1 year and Adolescents: IV: 30 mg/kg within 60 minutes prior to surgery (maximum: 2,000 mg per dose). Doses may be repeated in 4 hours if procedure is lengthy or if there is excessive blood loss (Bratzler 2013).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F29768949\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F29768950\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IM, IV: Adults: Following initial dose, maintenance doses should be given as follows: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">CrCl 10 to 30 mL/minute: 50% of usual dose at the usual interval </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">CrCl &lt;10 mL/minute: 25% of usual dosage at the usual interval </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Intermittent hemodialysis (IHD): Dialyzable (20% to 50%): Loading dose of 500 mg, 1 g, or 2 g, followed by 25% of initial dose at usual interval; for serious/life-threatening infections, administer 12.5% of initial dose after each hemodialysis session (given in addition to the maintenance doses). Alternatively, may administer 500 mg every 12 hours (Heintz, 2009). <b>Note:</b> Dosing dependent on the assumption of  3 times/week, complete IHD sessions. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Peritoneal dialysis (PD): Administer as for CrCl &lt;10 mL/minute (Aronoff, 2007)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Continuous renal replacement therapy (CRRT) (Heintz, 2009; Trotman, 2005): Drug clearance is highly dependent on the method of renal replacement, filter type, and flow rate. Appropriate dosing requires close monitoring of pharmacologic response, signs of adverse reactions due to drug accumulation, as well as drug concentrations in relation to target trough (if appropriate). The following are general recommendations only (based on dialysate flow/ultrafiltration rates of 1 to 2 L/hour and minimal residual renal function) and should not supersede clinical judgment:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">CVVH: Loading dose of 2 g followed by 1 to 2 g every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">CVVHD/CVVHDF: Loading dose of 2 g followed by either 1 g every 8 hours <b>or</b> 2 g every 12 hours (Heintz, 2009)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F29768951\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">No dosage adjustment provided in manufacturer&rsquo;s labeling. Use with caution (minor hepatic elimination occurs).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F29768966\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Azactam in Dextrose: 1 g (50 mL); 2 g (50 mL) [sodium free]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Injection: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Azactam: 1 g (1 ea); 2 g (1 ea) [sodium free]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 1 g (1 ea); 2 g (1 ea)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F29768893\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">May be product dependent</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F29768952\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Injection: Doses &gt;1 g should be administered IV </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">IM: Administer by deep injection into large muscle mass, such as upper outer quadrant of gluteus maximus or the lateral part of the thigh </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">IV: Administer by slow IV push over 3 to 5 minutes or by intermittent infusion over 20 to 60 minutes.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F29768899\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;margin-left:0em;display:inline\">Treatment of patients with urinary tract infections, lower respiratory tract infections, septicemia, skin/skin structure infections, intra-abdominal infections, and gynecological infections caused by susceptible gram-negative bacilli</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F30151325\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Osteomyelitis, native vertebral; Surgical prophylaxis (perioperative)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F29768883\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Aztreonam may be confused with azidothymidine</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F29768914\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Hematologic &amp; oncologic: Neutropenia (children 3% to 11%; adults &lt;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Hepatic: Increased serum transaminases (children, high dose: &gt;3 times ULN: 15% to 20%; children, standard dose: increased serum AST 4%, increased serum ALT 7%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Local: Pain at injection site (children 12%, adults 2%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cardiovascular: Phlebitis (intravenous: &le;2%), thrombophlebitis (intravenous: &le;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Dermatologic: Skin rash (children 4%, adults &le;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Gastrointestinal: Diarrhea (&le;1%), nausea (&le;1%), vomiting (&le;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Hematologic &amp; oncologic: Eosinophilia (children 6%, adults &lt;1%), thrombocythemia (children 4%, adults &lt;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Local: Erythema at injection site (intravenous: Children 3%, adults &lt;1%), discomfort at injection site (intramuscular: &le;2%), swelling at injection site (intramuscular: &le;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Renal: Increased serum creatinine (children 6%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Miscellaneous: Fever (&le;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">&lt;1%, postmarketing, and/or case reports: Abdominal cramps, anaphylaxis, anemia, angioedema, breast tenderness, bronchospasm, chest pain, <i>Clostridium difficile</i> associated diarrhea, confusion, diaphoresis, diplopia, dizziness, dysgeusia, dyspnea, erythema multiforme, exfoliative dermatitis, flushing, gastrointestinal hemorrhage, halitosis, headache, hepatitis, hepatobiliary disease, hypotension, increased serum alkaline phosphatase, increased serum ALT (adults), increased serum AST (adults), induration at injection site, insomnia, jaundice, leukocytosis, malaise, myalgia, nasal congestion, numbness of tongue, oral mucosa ulcer, pancytopenia, paresthesia, petechia, positive direct Coombs test, prolonged partial thromboplastin time, prolonged prothrombin time, pruritus, pseudomembranous colitis, purpura, seizure, sneezing, thrombocytopenia, tinnitus, toxic epidermal necrolysis, urticaria, vaginitis, ventricular bigeminy (transient), ventricular premature contractions (transient), vertigo, vulvovaginal candidiasis, weakness, wheezing</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F29768911\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to aztreonam or any component of the formulation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F29768912\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Beta-lactam allergy: Rare cross-allergenicity to penicillins, cephalosporins, or carbapenems may occur; use with caution in patients with a history of hypersensitivity to beta-lactams.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Superinfection: Prolonged use may result in fungal or bacterial superinfection, including <i>C. difficile</i>-associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed &gt;2 months postantibiotic treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Renal impairment: Use the injectable formulation with caution in patients with renal impairment; dosing adjustment required.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Toxic epidermal necrolysis: Use with caution in bone marrow transplant patients with multiple risk factors for toxic epidermal necrolysis (TEN) (eg, sepsis, radiation therapy, drugs known to cause TEN); rare cases of TEN in this population have been reported.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F29768921\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F29768918\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=104068&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Antibiotics may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG Vaccine (Immunization): Antibiotics may diminish the therapeutic effect of BCG Vaccine (Immunization). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cholera Vaccine: Antibiotics may diminish the therapeutic effect of Cholera Vaccine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lactobacillus and Estriol: Antibiotics may diminish the therapeutic effect of Lactobacillus and Estriol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Vaccination with live attenuated typhoid vaccine (Ty21a) should be avoided in patients being treated with systemic antibacterial agents.  Use of this vaccine should be postponed until at least 3 days after cessation of antibacterial agents.<i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F29768906\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">B (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F29768907\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have not been observed in animal reproduction studies. Aztreonam crosses the placenta and can be detected in the fetus.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F29768908\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Aztreonam is excreted into breast milk in concentrations &lt;1% of the corresponding maternal serum concentration. The manufacturer suggests consideration be given to temporarily discontinuing nursing during therapy.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F29768957\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Injection: Periodic liver function test; monitor for signs of anaphylaxis during first dose</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F29768931\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Inhibits bacterial cell wall synthesis by binding to one or more of the penicillin-binding proteins (PBPs) which in turn inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell walls, thus inhibiting cell wall biosynthesis. Bacteria eventually lyse due to ongoing activity of cell wall autolytic enzymes (autolysins and murein hydrolases) while cell wall assembly is arrested. Monobactam structure makes cross-allergenicity with beta-lactams unlikely.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F29768933\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: IM: Well absorbed; IM and IV doses produce comparable serum concentrations</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: Injection: Widely into body tissues, cerebrospinal fluid, bronchial secretions, peritoneal fluid, bile, and bone</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">V<sub>d</sub>: Neonates: 0.26 to 0.36 L/kg; Children: 0.2 to 0.29 L/kg; Adults: 0.2 L/kg </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Relative diffusion of antimicrobial agents from blood into CSF: Good only with inflammation (exceeds usual MICs)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">CSF:blood level ratio: Meninges: Inflamed: 8% to 40%; Normal: ~1% </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: 56%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Injection: Hepatic (minor %)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: Injection:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Neonates: &lt;7 days, &le;2.5 kg: 5.5 to 9.9 hours; &lt;7 days, &gt;2.5 kg: 2.6 hours; 1 week to 1 month: 2.4 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Children 2 months to 12 years: 1.7 hours </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Children with cystic fibrosis: 1.3 hours </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Adults: Normal renal function: 1.7 to 2.9 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">End-stage renal disease (ESRD): 6 to 8 hours </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak: IM, IV push: Within 60 minutes; IV infusion: 1.5 hours </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Injection: Urine (60% to 70% as unchanged drug); feces (~13% to 15%)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F29768968\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Azactam in Dextrose Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 g (50 mL): $39.93</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2 g (50 mL): $79.96</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Azactam Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 g (1): $34.80</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2 g (1): $69.60</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Aztreonam Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 g (1): $32.77</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2 g (1): $65.54</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45040497\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Atreon (BD);</li>\n      <li>Azactam (AT, AU, BB, BE, BH, CH, CN, DK, EG, ES, FI, FR, GB, GR, JO, LB, LU, MT, NO, NZ, PK, PT, QA, SE, SG, TW, VE, ZA);</li>\n      <li>Azanem (BR);</li>\n      <li>Azenam (IN, LK);</li>\n      <li>Azeus (BR);</li>\n      <li>Aznam (RU);</li>\n      <li>Azom (IN);</li>\n      <li>Azonam (BD);</li>\n      <li>Aztram (PH);</li>\n      <li>Aztreo (IN);</li>\n      <li>Aztreobol (RU);</li>\n      <li>Bencipen (PE);</li>\n      <li>Finacide (PT);</li>\n      <li>Mezactam (KR);</li>\n      <li>Monobac (MX);</li>\n      <li>Primbactam (IT);</li>\n      <li>Reonam (BD);</li>\n      <li>SG-Nam (LK);</li>\n      <li>Treonam (PE);</li>\n      <li>Vebac (ID)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Aronoff GR, Bennett WM, Berns JS, et al, <i>Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children</i>, 5th ed, Philadelphia, PA: American College of Physicians, 2007.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Azactam (aztreonam) injection [prescribing information]. Princeton, NJ: Bristol-Myers Squibb; June 2013.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Berbari EF, Kanj SS, Kowalski TJ, et al; Infectious Diseases Society of America. 2015 Infectious Diseases Society of America (IDSA) Clinical Practice Guidelines for the diagnosis and treatment of native vertebral osteomyelitis in adults. <i>Clin Infect Dis</i>. 2015;61(6):e26-e46.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aztreonam-systemic-drug-information/abstract-text/26229122/pubmed\" target=\"_blank\" id=\"26229122\">26229122</a>]</span><span class=\"doi\">10.1093/cid/civ482</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bosso JA and Black PG, &ldquo;The Use of Aztreonam in Pediatric Patients: A Review,&rdquo; <i>Pharmacotherapy</i>, 1991, 11(1):20-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aztreonam-systemic-drug-information/abstract-text/1902290/pubmed\" target=\"_blank\" id=\"1902290\">1902290</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bratzler DW, Dellinger EP, Olsen KM, et al, &ldquo;Clinical Practice Guidelines for Antimicrobial Prophylaxis in Surgery,&rdquo; <i>Am J Health Syst Pharm</i>, 2013, 70(3):195-283.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aztreonam-systemic-drug-information/abstract-text/23327981/pubmed\" target=\"_blank\" id=\"23327981\">23327981</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Brogden RN and Heel RC, &ldquo;Aztreonam. A Review of Its Antibacterial Activity, Pharmacokinetic Properties and Therapeutic Use,&rdquo; <i>Drugs</i>, 1986, 31(2):96-130.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aztreonam-systemic-drug-information/abstract-text/3512234/pubmed\" target=\"_blank\" id=\"3512234\">3512234</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Creasey WA, Platt TB, Frantz M, et al, &ldquo;Pharmacokinetics of Aztreonam in Elderly Male Volunteers,&rdquo; <i>Br J Clin Pharmacol</i>, 1985, 19:233-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aztreonam-systemic-drug-information/abstract-text/4039189/pubmed\" target=\"_blank\" id=\"4039189\">4039189</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    DHHS Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents. Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. October 2014. Available at <a href=\"http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf\" target=\"_blank\">http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf</a>. Accessed November 12, 2014</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Heintz BH, Matzke GR, Dager WE, &ldquo;Antimicrobial Dosing Concepts and Recommendations for Critically Ill Adult Patients Receiving Continuous Renal Replacement Therapy or Intermittent Hemodialysis,&rdquo; <i>Pharmacotherapy</i>, 2009, 29(5):562-77.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aztreonam-systemic-drug-information/abstract-text/19397464/pubmed\" target=\"_blank\" id=\"19397464\">19397464</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kalil AC, Metersky ML, Klompas M, et al. Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society [published online July 14, 2016]. <i>Clin Infect Dis</i>. doi: 10.1093/cid/ciw353.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aztreonam-systemic-drug-information/abstract-text/27418577/pubmed\" target=\"_blank\" id=\"27418577\">27418577</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lipsky BA, Berendt AR, Cornia PB, et al, &quot;2012 Infectious Diseases Society of America Clinical Practice Guideline for the Diagnosis and Treatment of Diabetic Foot Infections,&quot; <i>Clin Infect Dis</i>, 2012, 54(12):e132-73.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aztreonam-systemic-drug-information/abstract-text/22619242/pubmed\" target=\"_blank\" id=\"22619242\">22619242</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Settler FR, Schramm M, and Swabb EA, &ldquo;Safety of Aztreonam and SQ 26,992 in Elderly Patients With Renal Insufficiency,&rdquo; <i>Rev Infect Dis</i>, 1985, (Suppl 4):5622.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Solomkin JS, Mazuski JE, Bradley JS, et al. Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America. Clin Infect Dis. 2010;50(2):133-64.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aztreonam-systemic-drug-information/abstract-text/20034345 /pubmed\" target=\"_blank\" id=\"20034345 \">20034345 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Stutman HR, Chartrand SA, Tolentino T, et al, &ldquo;Aztreonam Therapy for Serious Gram-Negative Infections in Children,&rdquo; <i>Am J Dis Child</i>, 1986, 140(11):1147-51.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aztreonam-systemic-drug-information/abstract-text/3766490/pubmed\" target=\"_blank\" id=\"3766490\">3766490</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Trotman RL, Williamson JC, Shoemaker DM, et al, &quot;Antibiotic Dosing in Critically Ill Adult Patients Receiving Continuous Renal Replacement Therapy,&quot; <i>Clin Infect Dis</i>, 2005, 41(8):1159-66.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aztreonam-systemic-drug-information/abstract-text/16163635/pubmed\" target=\"_blank\" id=\"16163635\">16163635</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tunkel AR, Hartman BJ, Kaplan SL, et al, &ldquo;Practice Guidelines for the Management of Bacterial Meningitis,&rdquo; <i>Clin Infect Dis</i>, 2004, 39(9):1267-84.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aztreonam-systemic-drug-information/abstract-text/15494903/pubmed\" target=\"_blank\" id=\"15494903\">15494903</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zobell JT, Young DC, Waters CD, et al. Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: I. aztreonam and carbapenems. <i>Pediatr Pulmonol</i>. 2012;47(12):1147-1158.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aztreonam-systemic-drug-information/abstract-text/22911974 /pubmed\" target=\"_blank\" id=\"22911974 \">22911974 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zobell JT, Young DC, Waters CD, et al. ptimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: VI. Executive Summary. <i>Pediatr Pulmonol</i>. 2013;48(6):525-537.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aztreonam-systemic-drug-information/abstract-text/23359557/pubmed\" target=\"_blank\" id=\"23359557\">23359557</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 104068 Version 37.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F29768890\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F29768895\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F29768948\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F29768947\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F29768949\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F29768950\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F29768951\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F29768966\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F29768893\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F29768952\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F29768899\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F30151325\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F29768883\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F29768914\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F29768911\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F29768912\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F29768921\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F29768918\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F29768906\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F29768907\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F29768908\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F29768957\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F29768931\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F29768933\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F29768968\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F45040497\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/104068|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=aztreonam-systemic-patient-drug-information\" class=\"drug drug_patient\">Aztreonam (systemic): Patient drug information</a></li><li><a href=\"topic.htm?path=aztreonam-systemic-pediatric-drug-information\" class=\"drug drug_pediatric\">Aztreonam (systemic): Pediatric drug information</a></li></ul></div></div>","javascript":null}